Clinical Trial: TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Brief Summary: This multiple-center, randomized, 2-part, single- and double-blind study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.
Detailed Summary:
Sponsor: Theravance Biopharma R & D, Inc.
Current Primary Outcome: Seated systolic blood pressure [ Time Frame: 6 to 8 hours after drug administration ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Adverse Events [ Time Frame: 57 days ]
Original Secondary Outcome: Same as current
Information By: Theravance Biopharma R & D, Inc.
Dates:
Date Received: March 7, 2016
Date Started: May 2016
Date Completion: March 2017
Last Updated: July 11, 2016
Last Verified: July 2016